Clinical Trials
3 trialsNCT06543381 2026-03-05
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT06566742 2026-03-04
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04013880 2020-07-07
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Phase 1/2 Withdrawn